Tag: AEF0117
Aelis Farma announces the finalization of patient recruitment for the phase 2b study with AEF0117 in the treatment of cannabis addiction – 01/09/2024 at 6:00 p.m.
• As planned, 333 patients were randomized by the end of December 2023 across 11 clinical centers in the United States • This important milestone should make it possible to…
Aelis Farma: positive results from non-clinical regulatory studies for the entry of AEF0117 into a phase 3 clinical study – 07/11/2023 at 6:35 p.m.
Positive results from in vivo toxicological studies in which AEF0117 demonstrates a very favorable therapeutic index, more than 13,000 times higher than the active dose Finalization of the development of…
Aelis Farma: positive opinion from the DSMB for the continuation of the phase 2b clinical study with AEF0117 in cannabis addiction – 07/05/2023 at 07:00
Aelis Farma receives the positive opinion of the DSMB for the continuation without change to the protocol of its phase 2b clinical study with AEF0117 in cannabis addiction The excellent…
Aelis Farma: promising results for AEF0117
(CercleFinance.com) – Aelis Farma announces today the publication of a series of studies around AEF0117, its first drug candidate dedicated to the treatment of disorders related to excessive cannabis consumption…